Annexon Inc (US:ANNX) — Company Overview, News & Financial Data
Annexon is a biopharmaceutical company developing novel therapies for autoimmune and neurodegenerative disorders targeting key immune pathways.
About Annexon Inc
Annexon (NASDAQ:ANNX) is a biopharmaceutical company focused on developing novel therapies for patients with autoimmune and neurodegenerative disorders. Their innovative approach targets the classical complement cascade, a crucial part of the immune system, aiming to halt or prevent the progression of these conditions. The company's portfolio includes several candidates in clinical trials, targeting diseases like Guillain-Barre Syndrome, amyotrophic lateral sclerosis (ALS), and Huntington's disease, among others. With a commitment to transforming the lives of patients through groundbreaking research, Annexon's objective is to pioneer treatments that can significantly improve outcomes for individuals facing these challenging diseases.
Snapshot
Operations
Produtos e/ou serviços de Annexon Inc
- ANX005: This drug candidate is likely in development for treating a specific classical complement-mediated disorder.
- ANX007: Similar to ANX005, this is an investigational drug candidate targeting another classical complement-mediated disorder.
- ANX1502: This candidate focuses on a different approach. It might be an oral small molecule inhibitor of the classical complement pathway, potentially for a broader range of classical complement-mediated disorders compared to ANX005 or ANX007.
- ANX009: This investigational drug candidate is likely targeted towards a specific classical complement-mediated disease affecting the eye or surrounding tissues (ophthalmic disease).
equipe executiva do Annexon Inc
- Mr. Douglas E. Love Esq., J.D.CEO, President & Director
- Dr. Ted Yednock Ph.D.Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board
- Dr. Jamie Dananberg M.D.Executive VP & Chief Medical Officer
- Ms. Jennifer Lew CPAExecutive VP, CFO & Corporate Secretary
- Dr. Dean R. Artis Ph.D.Chief Scientific Officer & Executive VP
- Mr. Michael Overdorf M.B.A.Executive VP & Chief Business Officer
- Mr. Henk-Andre Kroon M.D.Senior Vice President of Translational Medicine
- Mr. Shikhar Agarwal M.B.A.Senior VP & Head of Commercial
- Dr. Sunil Mehta Pharm.D.Senior VP of Medical Affairs
- Dr. Lloyd Clark M.D.Senior Vice President of Ophthalmology Strategy & Innovation